Avis Budget Group, Inc.

Avis Budget Group, Inc. (CAR) Market Cap

Avis Budget Group, Inc. has a market capitalization of $6.25B.

Price: $176.79

-0.01 (-0.01%)

Market Cap: 6.25B

NASDAQ · time unavailable

CEO: Brian J. Choi

Sector: Industrials

Industry: Rental & Leasing Services

IPO Date: 1983-09-14

Website: https://www.avisbudgetgroup.com

Avis Budget Group, Inc. (CAR) - Company Information

Market Cap: 6.25B|Sector: Industrials

Company Profile

Avis Budget Group, Inc., together with its subsidiaries, provides car and truck rentals, car sharing, and ancillary products and services to businesses and consumers. It operates the Avis brand, that offers vehicle rental and other mobility solutions to the premium commercial and leisure segments of the travel industry; the Budget Truck brand, a local, and one-way truck and cargo van rental businesses with a fleet of approximately 20,000 vehicles, which are rented through a network of approximately 465 dealer-operated and 385 company-operated locations that serve the consumer and light commercial sectors in the continental United States; and the Zipcar brand, a car sharing network. The company also operates various other car rental brands, such as Budget, Payless, Apex, Maggiore, MoriniRent, FranceCars, Amicoblue, Turiscar, and ACL Hire. In addition, it offers optional insurance products and coverages, such as supplemental liability, personal accident, personal effects protection, emergency sickness protection, and automobile towing protection and cargo insurance products; fuel service options, roadside assistance services, electronic toll collection services, curbside delivery, tablet rentals, access to satellite radio, portable navigation units, and child safety seat rentals; automobile towing equipment and other moving accessories, such as hand trucks, furniture pads, and moving supplies; and Business Intelligence solution, an online portal for corporate travel. Avis Budget Group, Inc. operates in approximately 10,400 locations worldwide. The company was formerly known as Cendant Corporation and changed its name to Avis Budget Group, Inc. in September 2006. Avis Budget Group, Inc. was founded in 1946 and is headquartered in Parsippany, New Jersey.

Analyst Sentiment

18%
Underperform

From 8 Active Polls

1Y Forecast: $124.83

▼ -29.4% Potential Upside

Consensus Target Metrics

Low Bound

$85

Median

$133

High Bound

$160

Average

$125

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$124.83
▼ -29.39% Upside
Low Target
$85.00
-52% Risk
Median Target
$132.50
-25% Mid
High Target
$160.00
-9% Max
Consensus
Hold
2 / 13 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)6,2455,1494,5175,6525,9512,6722,8373,1093,606
Enterprise Value ($M)33,38932,29335,16233,67934,64728,54828,34129,33630,687
Price to Earnings Ratio (P/E)-9.36-4.55-1.513.94371.91-1.32-0.363.2864.39
Price/Earnings-to-Growth Ratio (PEG)0.2514.840.233.30
Price to Sales Ratio (P/S)0.532.031.701.611.961.101.050.891.18
Price to Book Ratio (P/B)-1.83-1.51-1.44-2.36-2.17-0.95-1.22-13.06-7.36
Price to Free Cash Flow Ratio (P/FCF)-4.08-1.670.63-3.82-1.42-0.83-2.83-141.34-1.83
Enterprise Value to Sales (EV/Sales)12.7613.209.5711.4011.7510.468.4310.07
Enterprise Value to EBITDA (EV/EBITDA)6.3130.3231.1719.6025.1128.10-19.1816.8923.53
Debt to Equity Ratio5.13-8.10-9.96-11.92-10.65-9.35-11.19-112.74-56.32
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-22.5%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for CAR. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 AVIS BUDGET GROUP INC (CAR) — Investment Overview

🧩 Business Model Overview

Avis Budget Group operates a vehicle rental and mobility platform with two primary revenue engines: (1) short-term rentals (leisure travel, airport and downtown locations) and (2) longer-term rentals (including commercial and travel-related accounts). The business converts large fleet assets into revenue through a dense distribution network (rental locations and counterparties), reservation systems, and channel partnerships.

Economically, the value chain centers on fleet acquisition and disposition. Rental demand drives vehicle utilization and pricing discipline, while fleet procurement terms, depreciation assumptions, maintenance costs, and end-of-life remarketing outcomes determine unit economics.

💰 Revenue Streams & Monetisation Model

  • Rental revenue (primary driver): Transactional pricing per day/mileage, influenced by demand seasonality, fleet availability, and competitive pricing.
  • Ancillary revenue: Optional add-ons (e.g., insurance products, vehicle accessories, upgrades, fees) that improve revenue yield per rental day.
  • Vehicle disposition/remarketing: Cash flows from selling used vehicles can materially offset depreciation and maintenance costs, turning a “cost of goods” problem into a margin driver.

Margin structure is dominated by (i) utilization and revenue yield, (ii) fleet costs (depreciation net of remarketing), (iii) maintenance and repair intensity, and (iv) financing and interest-rate environment affecting the cost of capital and fleet funding. The model is therefore highly operational: small shifts in fleet cost discipline and utilization can swing profitability.

🧠 Competitive Advantages & Market Positioning

Avis competes in a scale-intensive, asset-heavy industry where share gains are difficult to sustain without disciplined fleet management and reliable distribution. The most durable advantages tend to be operational “moats” rather than customer lock-in.

  • Cost advantages via fleet procurement and lifecycle management (economic moat): Scale supports better vehicle acquisition pricing, standardized maintenance processes, and tighter remarketing execution—lowering total cost per rental day.
  • Contractual and operational switching costs (moderate): Corporate and commercial accounts often operate through approved vendor lists, negotiated terms, and service-level requirements, reducing friction versus purely walk-in demand.
  • Distribution and network density: Broad airport and off-airport coverage improves availability and conversion, particularly when vehicle supply is constrained.

Competitive benchmarking (industry set):

  • Enterprise Holdings (National/Alamo): emphasizes strong dealer/remarketing capability and broad operational footprint.
  • The Hertz Corporation: large airport and fleet operations with significant fleet turnover mechanics.
  • Sixt (and other international operators): differentiated by brand positioning and certain markets, but subject to the same core fleet economics.

Avis focuses on maintaining efficient fleet utilization and cost discipline within a comparable “rental day” economics framework, striving to compete on availability, yield management, and lifecycle cost rather than relying on entrenched consumer switching costs or network effects.

🚀 Multi-Year Growth Drivers

  • Travel demand growth and business mobility cycles: Long-run travel expansion supports incremental rental days, with pricing power varying by capacity and supply constraints.
  • Expansion/reshaping of mobility needs: Growth in trips that substitute for ownership (especially where parking, lease structures, and lifestyle patterns make rentals more attractive) can increase addressable rental frequency.
  • Fleet optimization and technology-enabled demand capture: Yield management, reservations optimization, and better inventory allocation can translate into higher revenue per available vehicle.
  • Used-car market liquidity tailwind/mitigation: Remarketing scale and timing can reduce volatility in fleet residual outcomes; operational excellence improves resilience across economic cycles.

Over a 5–10 year horizon, the central question is whether Avis can sustain superior unit economics through fleet discipline and competitive yield management while managing the structural capital intensity of the fleet model.

⚠ Risk Factors to Monitor

  • Residual value and depreciation risk: Used vehicle prices, remarketing timing, and auction conditions can swing net fleet costs.
  • Interest-rate and funding risk: Fleet capital intensity makes borrowing costs and access to capital relevant for margins and strategic flexibility.
  • Capacity and pricing competition: Industry competition can lead to yield compression during demand softness or during aggressive capacity additions.
  • Operational execution risk: Maintenance costs, vehicle downtime, and claims handling directly affect cost per rental day.
  • Regulatory and compliance exposure: Consumer protection, insurance/claims regulations, and local compliance requirements affect costs and operational practices.
  • Customer behavior shifts and alternative mobility modes: Ride-hailing, subscription models, and changing travel patterns can alter mix and demand elasticity in specific geographies.

📊 Valuation & Market View

Equity valuation for car rental operators typically reflects the asset-heavy earnings profile and significant sensitivity to utilization, pricing yield, and net fleet costs. The market frequently frames value via multiples of EBITDA or earnings power that can be decomposed into fleet economics and operating leverage. Key valuation “drivers” include:

  • Durability of unit economics: sustainable revenue yield and disciplined fleet cost per rental day.
  • Volatility management: how effectively the firm hedges or mitigates residual value and remarketing swings.
  • Capital intensity and balance sheet structure: ability to fund fleet cycles without eroding returns.
  • Competitive positioning: capacity discipline and avoidance of structurally unprofitable pricing.

Because earnings are closely tied to fleet cycle outcomes and macro conditions, market expectations often hinge on normalization of fleet costs, the sustainability of utilization, and the credibility of operational improvements.

🔍 Investment Takeaway

Avis Budget Group is best understood as a fleet economics and distribution execution business. Its most credible long-term advantage comes from operational cost discipline across the vehicle lifecycle—procurement terms, maintenance intensity, utilization optimization, and remarketing outcomes—rather than from high consumer switching costs or network effects. The investment case rests on the ability to maintain resilient unit economics through varying demand and used-vehicle cycles while managing capital intensity and competitive pricing pressure.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CAR.

accessnewswire.com2026-06-04

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion  Company reported strong positive preclinical results demonstrating significantly enhanced anti-tumor activity of anti-CD-19 CAR T cells when combined with DNase I in multiple preclinical models of hematologic cancers Investigator initiated study to be conducted at Tel-Aviv Sourasky Medical Center ("Sourasky Center") FRAMINGHAM, MA / ACCESS Newswire / June 4, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (PeriNess), has informed the Company that it received formal approval from the Israeli Ministry of Health and the respective Institutional Review Board to conduct an exploratory clinical study of a combination systemic DNase I with anti-CD19 CAR T Cells in large B cell lymphoma (LBCL) patients.

globenewswire.com2026-06-02

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.

accessnewswire.com2026-06-01

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to improve CAR-T cell expansion, reduce exhaustion and enhance tumor control across hematologic cancer models Findings support continued clinical development of DNase I as a combinatorial strategy to augment CAR-T cell therapies in difficult-to-treat cancers Data to be presented today as a poster presentation at the ASCO 2026 annual meeting FRAMINGHAM, MA / ACCESS Newswire / June 1, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced positive preclinical data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. Presentation Details: Session Title: Hematologic Malignancies - Plasma Cell Dyscrasia (Poster Session) Abstract Title: Targeting cfDNA and NETs with DNase I to augment CAR-T cell function and antitumor efficacy Poster Board: 410 Presentation Date & Time: June 1, 2026, 9:00 AM - 12:00 PM CDT Presenter: Alexey V.

prnewswire.com2026-06-01

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidates Optimized CAR improved tumor targeting, internalization, and pharmacokinetics of 225Ac-labeled antibodies Lower-CAR conjugates preserved tumor targeting while reducing off-target liver and spleen uptake, supporting a wider therapeutic window that may enable higher, safer dosing Findings reinforce Actinium's proprietary radiochemistry expertise and directly support the Company's broader radioconjugate pipeline a capability that applies to every program from the platform NEW YORK, June 1, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, on May 31, 2026 presented new radiochemistry data at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting taking place in Los Angeles, California. The poster presented a systematic evaluation of chelator-to-antibody ratio (CAR) optimization for Actinium-225 (225Ac)-labeled antibody radioconjugates, a critical but often underappreciated design parameter that directly influences radiolabeling efficiency, antigen binding, internalization, and biodistribution.

zacks.com2026-05-29

Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?

Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?

gurufocus.com2026-05-28

A Look at Avis Budget Group Inc (CAR) After 5.9% Gain -- GF Value $130.88 vs Price $174.88

On May 28, 2026, Avis Budget Group Inc (CAR) shares rose by 5.9%, bringing the current price to $174.88. This latest movement comes amid a 52-week range that ha

zacks.com2026-05-28

CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities

Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.

globenewswire.com2026-05-27

Avis Budget Group Announces Pricing of $300 Million of Senior Notes

PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), priced a private offering of $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering. The Notes will be issued as additional notes under the Indenture, dated as of November 22, 2023, pursuant to which the Issuers previously issued $500 million aggregate principal amount of 8.000% Senior Notes due 2031. The Notes will have a maturity date of February 15, 2031. The closing of the offering of the Notes is expected to occur on May 29, 2026, subject to customary closing conditions. The Notes were priced at 100.500% of its face value and will be guaranteed on a senior unsecured basis by the Company and certain of its U.S. subsidiaries.

zacks.com2026-05-27

TTEC vs. Avis Budget: Which Turnaround Stock is Better Positioned?

TTEC's AI-driven turnaround, improving free cash flow and a stronger liquidity position it ahead of CAR's volatile recovery efforts.

globenewswire.com2026-05-27

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that it has exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercial-ready compounds as reagents, from its licensee, Wugen Inc. Wugen held exclusive worldwide rights to these two compounds for ex vivo, cell-based therapy applications.

globenewswire.com2026-05-27

Avis Budget Group Announces Intention to Offer $300 Million of Senior Notes

PARSIPPANY, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), intend, subject to market and other customary conditions, to offer $300 million aggregate principal amount of additional 8.000% Senior Notes due 2031 (the “Notes”) in a private offering.

marketbeat.com2026-05-27

Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances

Lyell Immunopharma NASDAQ: LYEL President and CEO Lynn Seely outlined the company's clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.

globenewswire.com2026-05-21

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting to be held in Chicago, IL, May 29 – June 2, 2026 and at the European Congress of Rheumatology being held in London, UK, June 3-6, 2026.

businesswire.com2026-05-20

Qihan Biotech Announces FDA Clearance of IND for QT-019C, a universal dual-target CAR-T candidate, marking a significant milestone in the development of a potentially low-lymphodepletion, off-the-shelf CAR-T therapy for autoimmune diseases

HANGZHOU, China--(BUSINESS WIRE)--Qihan Biotech, a biotechnology company dedicated to applying high-throughput, multiplexed gene editing technologies to cell therapy and organ transplantation, announced today that QT-019C has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). QT-019C is a universal allogeneic CAR-T cell therapy independently developed by Qihan Biotech using the company's proprietary intellectual property. A distinguishing innovat.

globenewswire.com2026-05-19

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress from June 3 – 6, 2026 in London. The five accepted abstracts will be delivered as one late-breaking oral presentation, one oral presentation, one poster view, one poster tour and one publication only.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CAR reported Q1’26 revenue of $2.53B and net income of -$283M (EPS -$8.01). Compared with Q1’25, revenue rose 4.1% YoY ($2.43B to $2.53B) while net income deteriorated materially (from -$505M to -$283M; still negative). QoQ, revenue declined 5.1% (Q4’25 $2.66B to Q1’26 $2.53B), and net losses narrowed slightly versus -$747M in Q4’25. Profitability was volatile: gross margin expanded sharply to 43.8% in Q1’26 from 19.3% in Q4’25, and operating income swung to +$767M (from +$168M in Q4’25), but pre-tax and net results remained negative due to -$340M income before tax and -$106M tax impacts (net margin -11.2%). Cash flow shows operating cash of $434M in Q1’26 versus $437M in Q4’25, with free cash flow also $434M (capex -$41M). The balance sheet remains highly leveraged: total assets fell to $10.46B from $32.19B in Q4’25, equity is still deeply negative at -$3.32B, and net debt is extremely high at ~$8.11B. Shareholder returns look strong: price is up 579% YoY (1y_change >20%), supporting a high total shareholder return contribution despite no dividends and no buybacks shown in the quarter. Analysts’ consensus target of ~$115.67 sits below the current price, implying a negative valuation setup."

Revenue Growth

Neutral

Revenue +4.1% YoY (Q1’26 $2.53B vs Q1’25 $2.43B). QoQ revenue -5.1% (Q4’25 $2.66B to Q1’26).

Profitability

Caution

Gross margin jumped to 43.8% from 19.3% QoQ, and operating income increased to $767M, but net income remains negative (-$283M; net margin -11.2%). EPS remains -$8.01.

Cash Flow Quality

Neutral

Operating cash flow was $434M in Q1’26 (roughly flat vs $437M QoQ). Free cash flow was positive in the quarter ($434M), supporting liquidity despite net losses.

Leverage & Balance Sheet

Neutral

Equity remains deeply negative (-$3.32B) and leverage is extreme (net debt ~$8.11B; total debt ~$8.64B). Current ratio ~0.74 indicates tight short-term coverage.

Shareholder Returns

Good

Strong price momentum: +579% over 1 year. Dividend paid is 0 in-quarter and no buybacks are indicated, but capital appreciation dominates total return.

Analyst Sentiment & Valuation

Neutral

Consensus target ($115.67) is well below the current price (~$493.86), suggesting limited near-term upside on standard target comparisons.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What?: Q1 2026 shows CAR’s (Avis per transcript) turnaround thesis landing operationally: Americas posted the first positive pricing in years with RPD +2.8% while rental days were flat, supported by deliberate fleet reduction (-0.6%) and better pricing discipline. Management highlighted record vehicle dispositions and fast depreciation normalization (monthly depreciation averaged ~$380, improving from >$500 in January). Financially, adjusted EBITDA beat plan by ~$50 million and full-year guidance was raised to $850m–$1.0b. The bigger “proof” is leverage and balance-sheet capacity: >$900m liquidity, ~$2.9b ABS capacity, and net leverage at 7.6x guided to <6x by year-end, with no corporate maturities until 2027. Key uncertainties remain recall constraints, geopolitical energy/mix effects, and used-car market competition that could pressure depreciation—hence management’s emphasis on nimble, class/timing-specific dispositions and partner-driven exits (Cox, plus Waymo and Avis First for longer-term mix upgrades).

AI IconGrowth Catalysts

  • Americas delivered first positive pricing quarter in 10 quarters: RPD +2.8% while rental days essentially flat
  • International mix shift produced RPD +3% constant-currency with rental days -3.8%
  • Fleet reduction aligned supply to demand: fleet -0.6% alongside TSA volumes +1.6%
  • Used-vehicle market strength enabled fleet right-sizing and faster depreciation normalization (monthly depreciation averaging ~$380 vs >$500 in January)
  • Avis First adoption ramped to 36 locations (9 international airports), supporting incremental higher-quality revenue

Business Development

  • Waymo partnership: on track for Dallas launch in Q3 2026; nearing public rider availability and discussing expansion to additional cities
  • Airport/real-estate commercial negotiations supporting Avis First expansion (details not quantified beyond 36 locations/9 international airports)
  • Vehicle disposition partnerships referenced: increased work with Cox on fleet disposition
  • Industry reference points: Hertz/Amazon described as an example of innovative disposition strategy

AI IconFinancial Highlights

  • Adjusted EBITDA exceeded plan by ~$50 million
  • Revenue +2.9% YoY in Americas; first Americas search increase in 10 quarters (per management phrasing)
  • Leisure share of revenue increased +1.1 percentage point in the quarter
  • Monthly depreciation in Americas averaged ~ $380 in Q1 2026 (improving from >$500 in January to mid-$300 by March)
  • Guidance raised: full-year adjusted EBITDA range increased to $850 million to $1 billion
  • Liquidity: >$900 million available liquidity plus ~$2.9 billion additional ABS capacity (as of Mar 31, 2026)
  • Leverage: net corporate leverage ratio 7.6x with target below 6x by year-end

AI IconCapital Funding

  • Refinancing in Q1: renewed European securitization facility ~EUR 2.4 billion, extended maturity by 2 years
  • Issued $668 million AESOP term debt across 3- and 5-year tenors to refinance maturing obligations (oversubscribed; favorable pricing)
  • Expect to renew $2.4 billion AESOP [VFN] facility end of month; add ~$480 million seasonal capacity through October 2026
  • No corporate debt maturities until 2027 (management stated)

AI IconStrategy & Ops

  • Deliberate fleet reduction to align supply with demand (fleet -0.6% vs TSA volumes +1.6%) to support pricing discipline
  • Speed over yield in vehicle dispositions to accelerate depreciation normalization (management cited write-down/disposition prioritization as driving Q1 EBITDA impact)
  • Focus on operational efficiency and utilization to peak under demand and avoid shoulder-period over-fleeting (structural shift vs peak-only approach)
  • Asset/usage management amid constraints: utilization highest in over 15 years for Q1 in Americas despite recall-related constraints and weather/TSA-related disruptions

AI IconMarket Outlook

  • Waymo: Dallas launch expected in Q3 2026; nearing public rider availability; further city expansion discussed
  • Demand: rental days in Americas trending mid-single-digit growth with RPD Holding; World Cup host cities described as strong early bookings
  • Confidence on pricing durability: management expects normalization after Easter mix impacts April and stabilizing into May/June
  • Easter timing: impacts Q2 comparisons; management indicated demand/days building encouraged into June/July/August

AI IconRisks & Headwinds

  • Recall-related constraints limiting operational flexibility while managing utilization
  • Geopolitical uncertainty (Middle East) impacting energy prices and potentially consumer behavior/mix
  • Industry-wide cost pressures previously inflating (labor/vehicle costs) and ongoing macro uncertainty affecting the used-car market and depreciation
  • Used-car supply competition risk tied to timing/classes of vehicles disposed; management emphasized need for nimbleness to maintain fleet cost targets
  • Stockholder/legal overhang: Pentwater acknowledged Section 16 short-swing rule violation and is in dispute posture; Avis stated it will pursue remedies

Q&A: Analyst Interest

  • Pricing sustainability & what slipped: Management attributed Q1 Americas pricing improvement to reduced supply discipline and selective fleet acceptance; Easter mix helped February/March, while April lapped those effects. They said pricing normalizes and stabilizes by May/June, citing continued constructive pricing trends into the second quarter.
  • Fleet strategy—continue fleeting under demand: Management confirmed a structural “fleet under demand” approach, not blanket under/over supply. They described peaking under events (e.g., Memorial Day) as a tactical point, while determining minimum fleet for shoulder periods relies on utilization and operational efficiency.
  • Fleet cost disposition mechanics & target “low 300s”: Management linked used-car supply variability and lease-return shifts to a need to sell by timing/vehicle class to protect depreciation. They cited more nimble holding/disposition, plus added partner work (Cox) and direct-to-consumer channels to offset rising new-car costs.

Sentiment: MIXED

Note: This summary was synthesized by AI from the CAR Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CAR.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CAR)

© 2026 Stock Market Info — Avis Budget Group, Inc. (CAR) Financial Profile